Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-VEGF Receptor 2 (Tyr1175) (19A10) Rabbit mAb 2478 40 µl
Western Blotting Immunohistochemistry Immunofluorescence
H M 230 Rabbit IgG
Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb 4060 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence Flow Cytometry
H M R Hm Mk Dm Z B 60 Rabbit IgG
Phospho-Src Family (Tyr416) (D49G4) Rabbit mAb 6943 40 µl
Western Blotting Immunoprecipitation
H M R Mk 60 Rabbit IgG
Phospho-FAK (Tyr397) (D20B1) Rabbit mAb 8556 40 µl
Western Blotting Immunoprecipitation
H 125 Rabbit IgG
Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb 4511 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence Flow Cytometry
H M R Mk Mi Pg Sc 43 Rabbit IgG
Phospho-PLCγ1 (Ser1248) (D25A9) Rabbit mAb 8713 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence Flow Cytometry
H M Mk 150 Rabbit IgG
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb 4370 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence Flow Cytometry
H M R Hm Mk Mi Dm Z B Dg Pg Sc 44, 42 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
Western Blotting
All Goat 

Product Description

The Angiogenesis Antibody Sampler Kit provides an economical means to investigate the angiogenic pathway downstream of VEGFR2. The kit contains enough primary antibody to perform four western blots per primary antibody.


Specificity / Sensitivity

Each antibody in the Angiogenesis Antibody Sampler Kit recognizes the phosphorylated form of its specific target. Phospho-FAK (Tyr397) (D20B1) Rabbit mAb may cross-react with overexpressed tyrosine phosphorylated proteins such as EGFR. Phospho-Src Family (Tyr416) (D49G4) Rabbit mAb may cross-react with other Src family members or overexpressed phosphorylated RTKs. Phospho-VEGFR2 (Tyr1175) (19A10) Rabbit mAb may cross-react with VEGFR1.


Source / Purification

Rabbit monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Ser473 of human Akt protein, Tyr397 of human FAK protein, Thr180/Tyr182 of human p38 MAPK protein, Thr202/Tyr204 of human p44 MAPK protein, Ser1248 of human PLCγ1 protein, Tyr416 of human Src protein, and Tyr1175 of human VEGFR2 protein.

Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Signaling from VEGFR2 is necessary for angiogenesis in vivo (2-4). Activation of the receptor leads to rapid recruitment of adaptor proteins, including Shc, GRB2, PI3 kinase, NCK, and the protein tyrosine phosphatases SHP-1 and SHP-2 (5). Phosphorylation of VEGFR2 at Tyr1212 provides a docking site for GRB2 binding and phosphorylation at Tyr1175 binds the p85 subunit of PI3 kinase and PLCγ (1,5,6). Activation of VEGFR2 during angiogenesis leads to signaling through multiple downstream kinase pathways including Akt, Src, FAK, p38, and Erk1/2 (2,7).


1.  Le Boeuf F et al. (2004) J Biol Chem 279, 39175–85

2.  Meyer, M. et al. (1999) EMBO J 18, 363-74.

3.  Takahashi, T. et al. (2001) EMBO J 20, 2768-78.

4.  Holmqvist, K. et al. (2004) J Biol Chem 279, 22267-75.

5.  Karkkainen, M.J. and Petrova, T.V. (2000) Oncogene 19, 5598-605.

6.  Rahimi, N. et al. (2000) J Biol Chem 275, 16986-92.

7.  Claesson-Welsh, L. (2003) Biochem Soc Trans 31, 20-4.


Entrez-Gene Id 207, 208, 10000, 5595, 5594, 5747, 2534, 3055, 3932, 4067, 5335, 1432, 5600, 5603, 6300, 6714, 3791, 7525
Swiss-Prot Acc. P31749, P31751, Q9Y243, P27361, P28482, Q05397, P06241, P08631, P06239, P07948, P19174, Q16539, Q15759, O15264, P53778, P12931, P35968, P07947

Protein Specific References

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Ou YH et al. (2011) Mol Cell 41, 458–70

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Syme CA et al. (2005) J Biol Chem 280, 11281–8

Li Z et al. (2001) J Biol Chem 276, 42226–32

Sonoda Y et al. (2000) J Biol Chem 275, 16309–15

Shikata Y et al. (2003) FASEB J 17, 2240–9

Lim Y et al. (2004) J Biol Chem 279, 29060–5

Le Boeuf F et al. (2004) J Biol Chem 279, 39175–85

Shikata Y et al. (2005) Exp Cell Res 304, 40–9

Cherubini A et al. (2005) Mol Biol Cell 16, 2972–83

Brunton VG et al. (2005) Cancer Res 65, 1335–42

Calandrella SO et al. (2005) J Cell Physiol 203, 103–10

Thomas M et al. (2010) J Biol Chem 285, 23842–9

Beierle EA et al. (2010) Cell Cycle 9, 1005–15

Koshman YE et al. (2011) Arterioscler Thromb Vasc Biol 31, 2432–40

Chen TH et al. (2011) Oncogene 30, 153–66

Higuchi M et al. (2013) J Cell Sci 126, 745–55

Nguyen TH et al. (2002) J Biol Chem 277, 24274–9

Alonso A et al. (2004) J Biol Chem 279, 4922–8

Chichili GR and Rodgers W (2007) J Biol Chem 282, 36682–91

Wagner MJ and Smiley JR (2009) J Virol 83, 12452–61

Motiwala T et al. (2010) J Cell Biochem 110, 846–56

Jin LL et al. (2010) J Proteome Res 9, 2752–61

Relou IA et al. (2003) J Biol Chem 278, 32638–44

Pillai VB et al. (2011) Mol Cell Biol 31, 2349–63

Ando K et al. (2011) J Biol Chem 286, 7619–28

Wang YH et al. (2001) Am J Physiol Cell Physiol 281, C1667–75

Schmitt JM and Stork PJ (2002) Mol Cell 9, 85–94

Zhou J et al. (2003) J Biol Chem 278, 6936–41

Abrahamsen H et al. (2003) J Biol Chem 278, 17170–7

Kim M et al. (2004) Oncogene 23, 1645–55

Zhou S et al. (2004) J Biol Chem 279, 54463–9

Ren Y et al. (2004) J Biol Chem 279, 8497–505

Kim HP et al. (2004) Biochem J 379, 141–50

Feistritzer C et al. (2005) Exp Cell Res 305, 214–20

Daoud G et al. (2006) J Physiol 571, 537–53

Eichhorn PJ et al. (2007) PLoS Genet 3, e218

Zhu S et al. (2007) Cancer Res 67, 10129–37

Zeng H et al. (2001) J Biol Chem 276, 32714–9

Ratcliffe KE et al. (2002) Oncogene 21, 6307–16

Fox SB et al. (2004) J Pathol 202, 313–20

Lamalice L et al. (2004) Oncogene 23, 434–45

Meyer RD et al. (2006) J Biol Chem 281, 867–75


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.
U.S. Patent No. 5,675,063.